KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
about
Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and diseaseMarkers of resistance to anti-EGFR therapy in colorectal cancerMolecular Profiling in Resectable Colorectal Liver Metastases: The Role of KRAS Mutation Status in Assessing Prognosis in the Preoperative SettingSerrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapyBRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapiesNew therapeutic strategies for BRAF mutant colorectal cancersMolecular profiling in the treatment of colorectal cancer: focus on regorafenibMolecular phenotypes of colorectal cancer and potential clinical applicationsPrecision medicine in colorectal cancer: the molecular profile alters treatment strategiesNew findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?Toward a Molecular Classification of Colorectal Cancer: The Role of BRAFMolecular alterations and biomarkers in colorectal cancerFuture directions for monitoring treatment response in colorectal cancerColorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular featuresColorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology ApproachBRAF mutations in advanced cancers: clinical characteristics and outcomesYttrium-90 radioembolization for colorectal cancer liver metastases in KRAS wild-type and mutant patients: Clinical and ccfDNA studies.BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies.RAS Mutations Beyond KRAS Exon 2: A Review and Discussion of Clinical Trial Data.The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.Genetic and Epigenetic Intra-tumour Heterogeneity in Colorectal CancerBRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer.The prognostic value of simultaneous tumor and serum RAS/RAF mutations in localized colon cancer.Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic studyKRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).Extramural vascular invasion and response to neoadjuvant chemoradiotherapy in rectal cancer: Influence of the CpG island methylator phenotype.K-RAS mutation profile in Puerto Rican patients with colorectal cancer: trends from April 2009 to January 2011.BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer.Characterization of rare transforming KRAS mutations in sporadic colorectal cancer.Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practicemiR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan.Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patientsPrimary and acquired resistance to biologic therapies in gastrointestinal cancers.A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma.Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trialMismatch repair deficiency endows tumors with a unique mutation signature and sensitivity to DNA double-strand breaks.The use of COLD-PCR and high-resolution melting analysis improves the limit of detection of KRAS and BRAF mutations in colorectal cancer.Genomic and biological characterization of exon 4 KRAS mutations in human cancer
P2860
Q24289344-2C611B52-CD53-435E-96DF-DC388273F73EQ24598640-4A456E8E-2C13-42BD-BD6A-12A54B760CF8Q26749002-56BC1D0B-0401-4610-AC75-E8D5B6916E99Q26751035-DD6A54E5-9543-4930-8EA2-F194F0E40E36Q26772276-CB3A7D1C-9457-4B98-8DF0-E8C8C890D2D1Q26772277-C41CBC3F-4865-41C5-BD0B-CAF8E98BBD85Q26778296-1A69728C-3A57-4258-97DE-B57E6D7011E9Q26785725-AA81E101-7BB5-4E65-AA77-BF0A452A7056Q26795558-E0D3838A-8DCB-4510-BACC-D439C332506BQ26796348-48532349-8869-4D19-9138-E4D90E25C01BQ26827212-259E6E12-B1B7-4E85-B564-7FDB8CDB6049Q26862317-6BC44A93-E32D-4ECA-BD7E-DE7691EB7635Q27008428-FE78E763-D21D-4EA3-8147-5DF74B0B8383Q28284149-B900C332-316A-4D68-8773-B2F505DF9EC6Q28647615-AB4964A4-0BF9-4804-8A66-BB1A955B856DQ28743591-427CB0F0-552C-4612-A2FE-DA5C9009B339Q30353464-78F719C3-E549-4F29-BDE2-CEA338B0DDFCQ30458424-1B0E0F4E-0F9C-448E-A432-9CFDCDC060A9Q30967175-2138D7BF-0A6F-4A85-B71D-97434A81F7CFQ33274011-CD3F7572-ADA8-4AA3-B639-3F3FBB691848Q33571591-C29B27B1-562F-4E5D-A983-E967E176BB6BQ33615076-45592659-DFE7-409E-8A82-8BDAB4DFBED9Q33679614-0BBFF3DE-1CF5-454E-AE6A-7CF4A9ADC4F5Q33682949-E9AD1337-5209-4A9E-BDD7-88C9A82FD0F0Q33693309-9194787A-2B7A-498A-9D20-9BC5A266FFD2Q33696207-850D8061-D1CF-43CD-9202-4B0E168A1650Q33703112-10BD2B5F-89F6-4571-8267-3A3E8420F83CQ33726858-5C4EDC27-280B-498C-A520-126DB1A55ED0Q33727871-67F002FF-501D-4B62-8953-B10F2AB3C348Q33732199-E74F607D-385D-47DA-A6E6-D9B9F87D3DEDQ33759960-92EAE302-BE13-459F-B84F-B70AA3767144Q33773806-5FCF1F89-2D5C-4771-B0E8-892E56F2D0BBQ33783108-73794EA7-11D2-42ED-998D-86676967C3EDQ33809458-039BADBC-5FFB-494C-8843-DAED3D6A7BEDQ33895573-E91EE9F9-F9B5-4A9E-A224-A768925086C9Q33945376-E6A0719C-D5DB-4321-903C-9EB4D2F8CE64Q33960370-E489F1F7-FB45-429B-A39A-93850078B39BQ34077139-CF4FBD42-E7B2-40BF-86E9-7C935428C15AQ34084873-564B04BF-FFCC-4869-8482-5650B6540649Q34145806-1116C701-3A47-409D-8653-DF962D5B9E4C
P2860
KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
KRAS and BRAF mutations in adv ...... ults from the MRC FOCUS trial.
@en
KRAS and BRAF mutations in adv ...... ults from the MRC FOCUS trial.
@en-gb
KRAS and BRAF mutations in adv ...... ults from the MRC FOCUS trial.
@nl
type
label
KRAS and BRAF mutations in adv ...... ults from the MRC FOCUS trial.
@en
KRAS and BRAF mutations in adv ...... ults from the MRC FOCUS trial.
@en-gb
KRAS and BRAF mutations in adv ...... ults from the MRC FOCUS trial.
@nl
prefLabel
KRAS and BRAF mutations in adv ...... ults from the MRC FOCUS trial.
@en
KRAS and BRAF mutations in adv ...... ults from the MRC FOCUS trial.
@en-gb
KRAS and BRAF mutations in adv ...... ults from the MRC FOCUS trial.
@nl
P2093
P50
P356
P1476
KRAS and BRAF mutations in adv ...... ults from the MRC FOCUS trial.
@en
P2093
Angela M Meade
Catherine L Daly
Faye Elliott
Graham Taylor
Matthew T Seymour
Philip Chambers
P304
P356
10.1200/JCO.2009.22.4295
P407
P577
2009-11-02T00:00:00Z